FluoroPharma Medical, Inc. engages in the discovery, development, and commercialization of proprietary medical diagnostic imaging products. The company is headquartered in Montclair, New Jersey and currently employs 4 full-time employees. The company went IPO on 2008-08-18. The firm is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). The company has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. The company measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD.
Follow-Up Questions
FluoroPharma Medical Inc (FPMI) の株価収益率はいくらですか？
FluoroPharma Medical Inc の株価収益率は 0 です。
FluoroPharma Medical Inc のCEOは誰ですか？
Dr. Thomas Tulip は FluoroPharma Medical Inc の Chief Executive Officer で、2015 から在籍しています。
FPMI の株価パフォーマンスは？
FPMI の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
FluoroPharma Medical Inc の主な事業テーマや業界は？
FluoroPharma Medical Inc は Biotechnology 業界、セクターは Health Care に属しています。
